BB-1709 / BlissBio - LARVOL DELTA

Preclinical studies of BB-1709, a CD73-targeting ADC potentially suppresses tumor growth through dual mechanisms (AACR 2025) - "Pharmacokinetic and toxicology assessments in non-human primates revealed a favorable safety profile for BB-1709 at clinically relevant dosages and administration schedules.In summary, these results suggest that BB-1709 not only exhibits good preclinical efficacy and safety, but also has the potential to promote anti-tumor immune responses by inhibiting CD73 enzymatic activity. A phase I clinical trial of BB-1709 is currently underway to further explore its therapeutic potential in cancer treatment."

Preclinical • Brain Cancer • CNS Tumor • Colorectal Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD73 • NT5E

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=300 | Recruiting | Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd

New P1 trial • Oncology • Solid Tumor